Anti-ALKBH5 Antibody, clone 6G7 ZooMAb^® Rabbit Monoclonal

rabbit

200

expressed in HEK 293 cells

unconjugated

purified antibody

primary antibodies

6G7, monoclonal
recombinant monoclonal

ZooMAb^® learn more

lyophilized

calculated mol wt ~ 52.26 and 43.05 kDa
observed mol wt ~71 and 79 kDa

human

horse, canine, bovine, monkey

antibody small pack of 25 μL

recombinant expression
Learn more about Antibody Enhanced Validation

ELISA: suitable
affinity binding assay: suitable
immunocytochemistry: suitable
western blot: suitable

IgG

ambient

2-8℃

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.

Clone 6G7 is a ZooMAb^® rabbit recombinant monoclonal antibody that specifically detects RNA demethylase ALKBH5. It targets an epitope within 17 amino acids from the C-terminal region. Predicted to react with all three isoforms.

KLH-conjugated linear peptide corresponding to 17 amino acids from the C-terminal region of human RNA demethylase ALKBH5.

Anti-ALKBH5, clone 6G7 ZooMAb^®, Cat. No. ZRB1053, is a recombinant Rabbit monoclonal antibody that specifically targets ALKBH5 and is tested for use in Affinity Binding Assay, ELISA, Immunocytochemistry, and Western Blotting.
Quality Control Testing

Evaluated by Western Blotting with GST-tagged human recombinant ALKBH5.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected GST-tagged human recombinant ALKBH5.

Tested Applications

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected ALKBH5 in HeLa cells.

Affinity Binding Assay: A representative lot of this antibody bound ALKBH5 peptides with a KD of 2.4 x 10-7 in an affinity binding assay.

ELISA: 0.5 μg/mL from a representative lot detected human recombinant ALKBH5.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Purified recombinant mouse monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

RNA demethylase ALKBH5 (UniProt: Q6P6C2; also known as EC:1.14.11.53, Alkylated DNA repair protein alkB homolog 5, Alpha-ketoglutarate-dependent dioxygenase alkB homolog 5) is encoded by the ALKBH5 (also known as ABH5, OFOXD1) gene (Gene ID: 54890) in human. ALKBH5 demethylates RNA by oxidative demethylation, specifically demethylates N6-methyladenosine (m6A) RNA, the most prevalent internal modification of mRNA in higher eukaryotes. Demethylation of m6A mRNA affects its processing and export. It is also reported to demethylate N6-methyladenosine in single-stranded DNA. For its demethylase activity, it requires molecular oxygen, alpha-ketoglutarate, and Fe2+ ions. Its alpha-ketoglutarate binding site is localized to amino acids 193-195. ALKBH5 is widely expressed, with highest expression observed in lung, followed by testis, pancreas, spleen, and ovary. Overexpression of ALKBH5 has been reported in multiple cancers, including breast cancer, glioblastoma, ovarian cancer, and gastric cancer. ALKBH5 knockout in tumor cells is shown to enhance the efficacy of immunotherapy (anti-PD-1 treatment) and prolonged survival in murine models. ALKBH5 knockout models exhibit increased m6A density and decreased mRNA expression, which leads to decreased gene expression or altered gene splicing. Some of these genes are involved in regulating VEGFa and TGFb1 in tumor microenvironment. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Li, N., et al. (2020). Proc. Natl. Acad. Sci. USA. 117(33); 20159-20170; Shen, C., et al. (2020). Cell Stem Cell. 27(1); 64-80).

Recommend storage of lyophilized product at 2-8℃; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8℃, or -20℃ for long term storage. Avoid repeated freeze-thaws.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

11 - Combustible Solids

WGK 1